The outlook of companies tied to the drug's legacy presents a intricate investment picture . While the initial surge generated substantial profits , generic alternatives have significantly eroded sales . Investing in related pharmaceutical companies now requires a discerning assessment of patent safeguards, evolving healthcare changes, and the pote